Precision/Personalized Medicine in Allergic Diseases and Asthma
- 384 Downloads
Like many other chronic diseases, every allergic patient has different characteristics based on clinical course, treatment responsiveness and disease outcomes, which are associated with the genetic and epigenetic control of molecular mechanisms and environment. This variability necessitates the establishment of patient-tailored and precision approaches in handling allergic disorders. Better understanding of the underlying pathophysiological mechanisms for the development of allergic disorders will provide more rationale strategies based on individual cases in controlling and treating these disorders. Endotyping, phenotyping, genotyping and theratyping, and biomarkers are keywords in this area and have been gaining lots of attention in the field of precision medicine, which aims to revolutionize patient care and develop better prevention and treatment strategies. In addition, precision health is a new concept that brings precise approaches to the scene for being healthy and prevention of allergic disease and asthma. The specialty of allergy has a leading role in the field, because allergen-specific immunotherapy started 105 years ago, and is historically a leading personalized/precision medicine approach in all medicine disciplines providing the possibility of cure in an individualized manner instead of conventional symptomatic treatments.
KeywordsAllergy Asthma Biomarker Endotype Phenotype Theratype Genotype Cytokines Precision medicine Personalized medicine
Innate lymphoid cells
The authors’ lab has been supported by Swiss National Science Foundation and Christine Kühne—Center for Allergy Research and Education.
Compliance with Ethical Standards
Conflict of interest
The authors declare no conflict of interest.
- Akdis CA, Akdis M (2015) Advances in allergen immunotherapy: aiming for complete tolerance to allergens. Sci Transl Med 7:280ps286Google Scholar
- Akdis CA, Bachert C, Cingi C et al (2013) Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 131:1479–1490PubMedPubMedCentralGoogle Scholar
- Akdis M, Aab A, Altunbulakli C et al (2016) Interleukins (from IL-1 to IL-38), interferons, transforming growth factor beta, and TNF-alpha: Receptors, functions, and roles in diseases. J Allergy Clin Immunol 138:984–1010Google Scholar
- Bleecker ER, FitzGerald JM, Chanez P et al (2016) Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388:2115–2127PubMedGoogle Scholar
- Chupp GL, Bradford ES, Albers FC et al (2017) Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 5:390–400PubMedGoogle Scholar
- GINA Report (2018) http://ginasthma.org/2018-gina-report-global-strategy-for-asthma-management-and-prevention/. Accessed 5 Apr 2018
- Mjosberg J, Spits H (2016) Human innate lymphoid cells. J Allergy Clin Immunol 138:1265–1276Google Scholar
- Muraro A, Lemanske RF Jr, Hellings PW et al (2016) Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 137:1347–1358PubMedGoogle Scholar
- Muraro A, Lemanske RF Jr, Castells M et al (2017) Precision medicine in allergic disease-food allergy, drug allergy, and anaphylaxis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology. Allergy 72:1006–1021PubMedGoogle Scholar
- Normansell R, Walker S, Milan SJ et al (2014) Omalizumab for asthma in adults and children. Cochrane Database Syst Rev (1):CD003559Google Scholar
- Pfaar O, Bonini S, Cardona V et al (2018) Perspectives in allergen immunotherapy: 2017 and beyond. Allergy 73 Suppl 104:5–23Google Scholar